Drug Safety Associate

Corbus Pharmaceuticals is building its first in‑house pharmacovigilance team to support a growing late‑stage portfolio. The Drug Safety Associate I will serve as the primary ICSR case processor, managing end‑to‑end intake and data entry in Veeva Vault Safety and ensuring expedited regulatory submissions meet ICH E2B and FDA/EMA timelines. This is a hands‑on operational role ideal for a new‑to‑industry scientist eager to build deep PV expertise in a high‑growth biotech setting. This role is a hybrid role 3 days onsite and 2 days remote to Norwood, Ma. KEY RESPONSIBILITIES Case Processing & Data Entry: Receive, triage, and process all incoming IC RS—spontaneous, clinical trial, and literature— in Veeva Vault Safety. Perform MedDRA and WHODrug coding for adverse events, indications, and suspect/concomitant medications. Assess case seriousness, expectedness (per current IB/SmPC), and causality against source documents. Author or draft initial case narratives in accordance with ICH E2B(R3) and company SOPs. Submit 7-day and 15-day expedited IC RS to FDA, EMA, and other applicable health authorities within regulatory timelines. Database & Data Integrity: Maintain accurate and complete case records in Veeva Vault Safety; apply quality checks before lock. Execute follow‑up requests to clinical sites, reporters, and CROs for missing or incomplete case information. Support migration of legacy CSPC safety data (~260 cases across 4 studies) into Vault Safety. Reconcile cases against Veeva EDC and partner safety databases as required. Regulatory & Compliance Support: Assist in preparation of line listings and case data extracts for DSURs and PBRERs. Contribute to SOP authoring and maintenance as PV processes are established in‑house. Participate in audit and inspection readiness activities; retrieve case documentation as requested. Support periodic reconciliation activities with CRO and clinical partners. QUALIFICATIONS Required: Bachelor's degree in Pharmacy, Nursing, Life Sciences, or a related healthcare discipline. 3-4 years of experience in drug safety/pharmacovigilance, clinical research, or a related regulated life‑sciences role. Familiarity with ICH E2B, ICH E2A, FDA 21 CFR 312.32, and EMA GVP Module VI reporting requirements. Working knowledge of MedDRA terminology. Strong attention to detail and ability to manage regulatory deadlines. Preferred: Prior hands‑on experience in Veeva Vault Safety, Oracle Argus, or ARISg. Exposure to clinical trial environments (CRO, site, or sponsor side). Internship or co‑op experience in a pharmaceutical or biotech PV setting. Familiarity with safety‑EDC reconciliation workflows. Technical Skills: Veeva Vault Safety (or equivalent) — data entry and case processing. E2B(R3) electronic reporting via gateway (training provided if needed). Why Corbus: This is a foundational hire in a first‑in‑kind in‑house PV team. The successful candidate will have direct visibility into regulatory strategy, aggregate reporting, and signal management — exposure that typically takes years to obtain at larger organizations. Competitive compensation, a collaborative science‑driven culture, and a clear development pathway toward a Senior or Specialist role. Corbus is a close‑knit global team of high‑achieving, innovative, creative and, above all else, passionate employees. We hire for personality as well as for skill. At Corbus, we take pride in our “family” atmosphere where each person’s contribution is vital to our success. As a Corbus employee, you are empowered to think creatively and be proactive in your approach. There is no place for politics or red tape here. About Corbus: Corbus Pharmaceuticals Holdings, Inc. is a clinical‑stage biotechnology company focused on developing innovative therapies in oncology and obesity. Our mission is to help people defeat serious illness by advancing differentiated scientific approaches targeting well‑understood biological pathways with significant unmet medical need. Corbus’ lead oncology program, CRB-701, is a next‑generation antibody‑drug conjugate (ADC) targeting Nectin‑4‑expressing tumors and is being developed for multiple solid tumor indications. Our obesity program, CRB-913, is a highly peripherally restricted CB1 receptor inverse agonist designed to support meaningful weight loss while minimizing central nervous system side effects. Together, these programs reflect our commitment to advancing transformative therapies through rigorous science and clinical innovation. Headquartered in Norwood, Massachusetts, Corbus fosters a collaborative, entrepreneurial environment where employees are empowered to make meaningful contributions and help shape the future of the company. For more information, visit corbuspharma.com and connect with us on LinkedIn. Corbus Pharmaceuticals Holdings, Inc. is an equal opportunity employer. #J-18808-Ljbffr